They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Transcription

1 Managing neutropenic sepsis in secondary and tertiary care bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: NICE Pathway last updated: 30 August 2017 This document contains a single flowchart and uses numbering to link the boxes to the associated recommendations. Page 1 of 10

2 Page 2 of 10

3 1 Person with suspected neutropenic sepsis No additional information 2 Emergency treatment and assessment Treat suspected neutropenic sepsis as an acute medical emergency and offer empiric antibiotic therapy immediately. Include in the initial clinical assessment of patients with suspected neutropenic sepsis: history and examination full blood count, kidney and liver function tests (including albumin), C-reactive protein, lactate and blood culture. See what NICE says on acutely-ill patients in hospital and acute kidney injury. Further assessment After completing the initial clinical assessment (see above) try to identify the underlying cause of the sepsis by carrying out: additional peripheral blood culture in patients with a central venous access device if clinically feasible urinalysis in all children aged under 5 years. Do not perform a chest X-ray unless clinically indicated. Tests for rapidly identifying bloodstream bacteria and fungi The following recommendations are from NICE diagnostics guidance on tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay). There is currently insufficient evidence to recommend the routine adoption in the NHS of the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi. The tests show promise and further research to provide robust evidence is encouraged, particularly to demonstrate the value of using the test results in clinical decision-making (see sections 5.18 to 5.22 of NICE diagnostics guidance 20). Page 3 of 10

4 NICE has published a medtech innovation briefing on Fungitell for antifungal treatment stratification. Procalcitonin testing The following recommendations are from NICE diagnostics guidance on procalcitonin testing for diagnosing and monitoring sepsis. The procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay or VIDAS BRAHMS PCT assay) show promise but there is currently insufficient evidence to recommend their routine adoption in the NHS. Further research on procalcitonin tests is recommended for guiding decisions to: stop antibiotic treatment in people with confirmed or highly suspected sepsis in the intensive care unit or start and stop antibiotic treatment in people with suspected bacterial infection presenting to the emergency department. Centres currently using procalcitonin tests to guide these decisions are encouraged to participate in research and data collection (see section 6.25 of NICE diagnostics guidance 18). 3 Start antibiotic therapy All patients Offer beta lactam monotherapy with piperacillin with tazobactam 1 as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications. Do not offer an aminoglycoside, either as monotherapy or in dual therapy, for the initial empiric treatment of suspected neutropenic sepsis unless there are patient-specific or local microbiological indications. Empiric glycopeptide antibiotics in patients with central venous access devices Do not offer empiric glycopeptide antibiotics to patients with suspected neutropenic sepsis who have central venous access devices unless there are patient-specific or local microbiological indications. Page 4 of 10

5 1 At the time this guidance was created (September 2012) piperacillin with tazobactam did not have a UK marketing authorisation for use in children aged under 2 years. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The child's parent or carer should provide informed consent, which should be documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices and the prescribing advice provided by the Joint Standing Committee on Medicines (a joint committee of the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group) for further information. Page 5 of 10

6 Do not remove central venous access devices as part of the initial empiric management of suspected neutropenic sepsis. 4 Confirm diagnosis of neutropenic sepsis Diagnose neutropenic sepsis in patients having anticancer treatment whose neutrophil count is per litre or lower and who have either: a temperature higher than 38 C or other signs or symptoms consistent with clinically significant sepsis. 5 Assess the patient's risk of septic complications A healthcare professional with competence in managing complications of anticancer treatment should assess the patient's risk of septic complications within 24 hours of presentation to secondary or tertiary care, basing the risk assessment on presentation features and using a validated risk scoring system. Examples of risk scoring systems include the Multinational Association of Supportive Care in Cancer risk index and the modified Alexander rule for children. 6 Patient at low risk of septic complications Consider outpatient antibiotic therapy for patients with confirmed neutropenic sepsis and a low risk of developing septic complications, taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops. 7 Patient at high risk of septic complications For patients with confirmed neutropenic sepsis and a high risk of developing septic complications, a healthcare professional with competence in managing complications of anticancer treatment should daily: review the patient's clinical status reassess the patient's risk of septic complications, using a validated risk scoring system. Examples of risk scoring systems include the Multinational Association of Supportive Care in Cancer risk index and the modified Alexander rule for children. Page 6 of 10

7 Do not switch initial empiric antibiotics in patients with unresponsive fever unless there is clinical deterioration or a microbiological indication. 8 Patient whose risk of septic complications is reassessed as low Switch from intravenous to oral antibiotic therapy after 48 hours of treatment in patients whose risk of developing septic complications has been reassessed as low by a healthcare professional with competence in managing complications of anticancer treatment using a validated risk scoring system. Examples of risk scoring systems include the Multinational Association of Supportive Care in Cancer risk index and the modified Alexander rule for children. Consider outpatient antibiotic therapy for patients with confirmed neutropenic sepsis and a low risk of developing septic complications, taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops. 9 Duration of antibiotic treatment Continue inpatient empiric antibiotic therapy in all patients who have unresponsive fever unless an alternative cause of fever is likely. Discontinue empiric antibiotic therapy in patients whose neutropenic sepsis has responded to treatment, irrespective of neutrophil count. 10 Discharge Offer discharge to patients having empiric antibiotic therapy for neutropenic sepsis only after: the patient's risk of developing septic complications has been reassessed as low by a healthcare professional with competence in managing complications of anticancer treatment using a validated risk scoring system and taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops. Examples of risk scoring systems include the Multinational Association of Supportive Care in Cancer risk index and the modified Alexander rule for children. Page 7 of 10

8 Glossary Anticancer treatment given with the intent to reduce the level of cancer cells in a patient; it includes, but is not limited to, chemotherapy and radiotherapy Empiric an action undertaken prior to determination of the underlying cause of a problem Empiric antibiotic given to a person before a specific microorganism or source of the potential infection is known; it is usually a broad-spectrum antibiotic and the treatment may change if the microorganism or source is confirmed Empiric antibiotics given to a person before a specific microorganism or source of the potential infection is known; they are usually broad-spectrum antibiotics and the treatment may change if the microorganism or source is confirmed G-CSF granulocyte-colony stimulating factor; a type of protein that stimulates the bone marrow to make white blood cells (granulocytes) Sources : prevention and management in people with cancer (2012) NICE guideline CG151 Tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay) (2016) NICE diagnostics guidance 20 Procalcitonin testing for diagnosing and monitoring sepsis (2015) NICE diagnostics guidance 18 Page 8 of 10

9 Your responsibility Guidelines The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Technology appraisals The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take these recommendations fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this interactive flowchart is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Commissioners and/or providers have a responsibility to provide the funding required to enable the recommendations to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to Page 9 of 10

10 have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Medical technologies guidance, diagnostics guidance and interventional procedures guidance The recommendations in this interactive flowchart represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take these recommendations fully into account. However, the interactive flowchart does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Commissioners and/or providers have a responsibility to implement the recommendations, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this interactive flowchart should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Page 10 of 10